Anti-PD1-antibody and Pulsed HHI for Advanced BCC

Inclusion Criteria: * Informed Consent as documented by signature * Histologically or cytologically confirmed advanced BCC, defined as: a) metastasized BCC, b) locally advanced BCC, not suitable for surgical or radio-therapeutic treatment c) multiple BCCs (\>5) d) BCC \>10mm; not suitable for surgery or radiotherapy * Subjects must have an evaluable disease as measured by Immune-related Response criteria, or PERSIST (PET response criteria in solid tumours) criteria in patients with metastatic BCCs without cutaneous lesions. * Subjects (males and females) aged ≥ 18 years * Adequate organ function (hematologic, renal, hepatic), as assessed by the study physician. Deviations of the following parameters are allowed upon decision of the investigator in case that these are not considered to be of clinical relevance and/or don't represent organ dysfunction or correspond to allowed comorbidities as specified in section 7.1: * Absolute neutrophil count \>1.5 x 109/l * Hemoglobin \>9 g/dL * Platelets ≥ 100 x 109/l * Serum total bilirubin \<1.5 x Upper limit of normal (ULN) (or ≤3x ULN, if liver metastases). * Alanine transaminase (ALT) and Aspartate transaminase (AST) \< 3 x ULN or \<5 ULN if liver metastases are present * Patients with Gilbert's Disease and total bilirubin up to 3x ULN may be eligible after communication with and approval from the medical monitor * Alkaline phosphatase (ALP) ≤2.5x ULN (or ≤5x ULN, if liver or bone metastases) * Serum creatinine \< 2 x ULN * Creatine …